Johnson & Johnson EBITDA 2012-2026 | JNJ

Johnson & Johnson EBITDA for the quarter ending March 31, 2026 was $7.428B, a 19.79% increase year-over-year.

  • Johnson & Johnson 2025 EBITDA was 42.111B, a 61.26% increase from 2024.
  • Johnson & Johnson 2024 EBITDA was 26.113B, a 6.23% increase from 2023.
  • Johnson & Johnson 2023 EBITDA was 24.581B, a 9.28% decline from 2022.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

Johnson & Johnson EBITDA 2012-2026 | JNJ

  • Johnson & Johnson 2025 EBITDA was 42.111B, a 61.26% increase from 2024.
  • Johnson & Johnson 2024 EBITDA was 26.113B, a 6.23% increase from 2023.
  • Johnson & Johnson 2023 EBITDA was 24.581B, a 9.28% decline from 2022.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$887.6B
AbbVie (ABBV)$367.7B
Roche Holding AG (RHHBY)$318.8B
Merck (MRK)$299.9B
Novartis AG (NVS)$294B
Novo Nordisk (NVO)$167.5B
Pfizer (PFE)$153.1B
Sanofi (SNY)$114B
Bayer (BAYRY)$46.2B
Innoviva (INVA)$1.8B